Abstract
Machado–Joseph disease (MJD) is a late-onset neurodegenerative disorder that presents clinical heterogeneity not completely explained by its causative mutation. MJD is caused by an expansion of a CAG tract at exon 10 of the ATXN3 gene (14q32.1), which encodes for ataxin-3. The main goal of this study was to analyze the occurrence of alternative splicing at the ATXN3 gene, by sequencing a total of 415 cDNAs clones (from 20 MJD patients and 14 controls). Two novel exons are described for the ATXN3 gene. Fifty-six alternative splicing variants, generated by four types of splicing events, were observed. From those variants, 50 were not previously described, and 26 were only found in MJD patients samples. Most of the variants (85.7%) present frameshift, which leads to the appearance of premature stop codons. Thirty-seven of the observed variants constitute good targets to nonsense-mediated decay, the remaining are likely to be translated into at least 20 different isoforms. The presence of ataxin-3 domains was assessed, and consequences of domain disruption are discussed. The present study demonstrates high variability in the ATXN3 gene transcripts, providing a basis for further investigation on the contribution of alternative splicing to the MJD pathogenic process, as well as to the larger group of the polyglutamine disorders.
Similar content being viewed by others
References
Coutinho P (1992) Doença de Machado-Joseph: Tentativa de Definição. PhD Dissertation, Instituto de Ciências Biomédicas Abel Salazar, Porto
Coutinho P, Andrade C (1978) Autosomal dominant system degeneration in Portuguese families of the Azores Islands. Neurology 28:703–709
Takiyama Y, Nishizawa M, Tanaka H, Kawashima S, Sakamoto H, Karube Y, Shimazaki H, Soutome M, Endo K, Ohta S et al (1993) The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 4:300–304
Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I et al (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8:221–228
Ichikawa Y, Goto J, Hattori M, Toyoda A, Ishii K, Jeong SY, Hashida H, Masuda N, Ogata K, Kasai F et al (2001) The genomic structure and expression of MJD, the Machado-Joseph disease gene. J Hum Genet 46:413–422
Maciel P, Costa MC, Ferro A, Rousseau M, Santos CS, Gaspar C, Barros J, Rouleau GA, Coutinho P, Sequeiros J (2001) Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 58:1821–1827
Maciel P, Gaspar C, DeStefano AL, Silveira I, Coutinho P, Radvany J, Dawson DM, Sudarsky L, Guimarães J, Loureiro JE et al (1995) Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 57:54–61
Tzvetkov N, Breuer P (2007) Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes. Biol Chem 388:973–978
Riess O, Rüb U, Pastore A, Bauer P, Schöls L (2008) SCA3: neurological features, pathogenesis and animal models. Cerebellum 7:125–137
Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, Gotsdiner D, Fischbeck KH, Pittman RN (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41:453–462
Mauri PL, Riva M, Ambu D, De Palma A, Secundo F, Benazzi L, Valtorta M, Tortora P, Fusi P (2006) Ataxin-3 is subject to autolytic cleavage. FEBS J 273:4277–4286
Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336
Hiller M, Platzer M (2008) Widespread and subtle: alternative splicing at short-distance tandem sites. Trends Genet 24:246–255
Sorek R, Shamir R, Ast G (2004) How prevalent is functional alternative splicing in the human genome? Trends Genet 20:68–71
Hall TA (1999) BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95–98
Castrignano T, Rizzi R, Talamo IG, De Meo PD, Anselmo A, Bonizzoni P, Pesole G (2006) ASPIC: a web resource for alternative splicing prediction and transcript isoforms characterization. Nucleic Acids Res 34:W440–W443
Sali A, Potterton L, Yuan F, van Vlijmen H, Karplus M (1995) Evaluation of comparative protein modelling by MODELLER. Proteins 23:318–326
Russell RB, Barton GJ (1992) Multiple protein sequence alignment from tertiary structure comparison: assignment of global and residue confidence levels. Proteins 14:309–323
Gao K, Masuda A, Matsuura T, Ohno K (2008) Human branch point consensus sequence is yUnAy. Nucleic Acids Res 36(7):2257–2267
Maquat LE (2005) Nonsense-mediated mRNA decay in mammals. J Cell Sci 118(Pt 9):1773–1776
Gales L, Cortes L, Almeida C, Melo CV, Costa M do C, Maciel P, Clarke DT, Damas AM, Macedo-Ribeiro S (2005) Towards a structural understanding of the fibrillization pathway in Machado-Joseph’s disease: trapping early oligomers of non-expanded ataxin-3. J Mol Biol 353:642–654
Albrecht M, Golatta M, Wüllner U, Lengauer T (2004) Structural and functional analysis of ataxin-2 and ataxin-3. Eur J Biochem 271:3155–3170
Sahba S, Nechiporuk A, Figueroa KP, Nechiporu T, Pulst SM (1998) Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. Genomics 47:359–364
Affaitati A, de Cristofaro T, Feliciello A, Varrone S (2001) Identification of alternative splicing of spinocerebellar ataxia type 2 gene. Gene 267:89–93
Tadokoro K, Yamazaki-Inoue M, Tachibana M, Fujishiro M, Nagao K, Toyoda M, Ozaki M, Ono M, Miki N, Miyashita T, Yamada M (2005) Frequent occurrence of protein isoforms with or without a single amino acid residue by subtle alternative splicing: the case of Gln in DRPLA affects subcellular localization of the products. J Hum Genet 50:382–394
Tsunemi T, Ishikawa K, Jin H, Mizusawa H (2008) Cell-type-specific alternative splicing in spinocerebellar ataxia type 6. Neurosci Lett 447:78–81
Einum DD, Clark AM, Townsend JJ, Ptacek LJ, Fu YH (2003) A novel central nervous system-enriched spinocerebellar ataxia type 7 gene product. Arch Neurol 60:97–103
Katti MV, Sami-Subbu R, Ranjekar PK, Gupta VS (2000) Amino acid repeat patterns in protein sequences: their diversity and structural-functional implications. Protein Sci 9:1203–1209
Dorsman JC, Pepers B, Langenberg D, Kerkdijk H, Ijszenga M, den Dunnen JT, Roos RA, van Ommen GJ (2002) Strong aggregation and increased toxicity of polyleucine over polyglutamine stretches in mammalian cells. Hum Mol Genet 11:1487–1496
Toulouse A, Au-Yeung F, Gaspar C, Roussel J, Dion P, Rouleau GA (2005) Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts. Hum Mol Genet 14:2649–2660
Gaspar C, Jannatipour M, Dion P, Laganière J, Sequeiros J, Brais B, Rouleau GA (2000) CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum Mol Genet 9:1957–1966
Bettencourt C, Silva-Fernandes A, Montiel R, Santos C, Maciel P, Lima M (2007) Triplet repeats: features, dynamics and evolutionary mechanisms. In: Santos C, Lima M (eds) Recent advances in molecular biology and evolution: applications to biological anthropology. Research Signpost, Kerala, pp 83–114
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123:773–786
Rodrigues AJ, Coppola G, Santos C, Costa M do C, Ailion M, Sequeiros J, Geschwind DH, Maciel P (2007) Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J 21:1126–1136
Todi SV, Laco MN, Winborn BJ, Travis SM, Wen HM, Paulson HL (2007) Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J Biol Chem 282:29348–29358
Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL, Bonini NM (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 18:37–48
Goti D, Katzen SM, Mez J, Kurtis N, Kiluk J, Ben-Haïem L, Jenkins NA, Copeland NG, Kakizuka A, Sharp AH et al (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 24:10266–10279
Lin X, Antalffy B, Kang D, Orr HT, Zoghbi HY (2000) Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 3:157–163
Li F, Macfarlan T, Pittman RN, Chakravarti D (2002) Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J Biol Chem 277:45004–45012
Le Texier V, Riethoven JJ, Kumanduri V, Gopalakrishnan C, Lopez F, Gautheret D, Thanaraj TA (2006) AltTrans: transcript pattern variants annotated for both alternative splicing and alternative polyadenylation. BMC Bioinformatics 7:169
ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET et al (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799–816
Acknowledgments
This work was supported by “Projecto Regional Integrado, DMJ (PRI-DMJ)” (funded by Regional Government of the Azores), and “Transcriptional variation of the ATXN3 gene as modulator of the clinical heterogeneity in Machado–Joseph disease (MJD)” (PIC/IC/83074/2007, funded by “Fundação para a Ciência e a Tecnologia”, FCT). C.B. (SFRH/BD/21875/2005) is a recipient of a PhD grant, and C.S. (SFRH/BPD/20944/2004) and M.C.C. (SFRH/BPD/28560/2006) are postdoctoral fellows from FCT.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bettencourt, C., Santos, C., Montiel, R. et al. Increased transcript diversity: novel splicing variants of Machado–Joseph Disease gene (ATXN3). Neurogenetics 11, 193–202 (2010). https://doi.org/10.1007/s10048-009-0216-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10048-009-0216-y